

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of:</p> <p>Ashkenazi et al.</p> <p>Serial No.: Not yet assigned</p> <p>Filed: Herewith</p> <p>For: <i>Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same</i></p>	<p>Group Art Unit: Not yet assigned</p> <p>Examiner: Not yet assigned</p>
--	---

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to substantive examination of the above captioned patent application (which is filed herewith), and for calculation of the proper filing fee, Applicants respectfully request that the following amendments be entered.

Serial No.: Not yet assigned
Filed: Herewith

In the claims:

Please cancel Claims 1-38 without prejudice or disclaimer.

Please add new Claims 39-51 as follows.

--39. (New) An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263);
- (b) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263),

lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

40. (New) The isolated polypeptide of Claim 39 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263);
- (b) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263),

lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

Serial No.: Not yet assigned
Filed: Herewith

41. (New) The isolated polypeptide of Claim 39 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263);
- (b) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263),

lacking its associated signal peptide;

- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263);

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide; or

- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

42. (New) The isolated polypeptide of Claim 39 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263);
- (b) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263),

lacking its associated signal peptide;

- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263);

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide; or

- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

Serial No.: Not yet assigned
Filed: Herewith

43. (New) The isolated polypeptide of Claim 39 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263);
(b) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

44. (New) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263);
(b) the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

45 (New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263).

Serial No.: Not yet assigned
Filed: Herewith

46 (New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide.

47 (New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263).

48 (New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 98 (SEQ ID NO:263), lacking its associated signal peptide.

49 (New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

50. (New) A chimeric polypeptide comprising a polypeptide according to Claim 39 fused to a heterologous polypeptide.

51. (New) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.--

100%	100%
99%	99%
98%	98%
97%	97%
96%	96%
95%	95%
94%	94%
93%	93%
92%	92%
91%	91%
90%	90%
89%	89%
88%	88%
87%	87%
86%	86%
85%	85%
84%	84%
83%	83%
82%	82%
81%	81%
80%	80%
79%	79%
78%	78%
77%	77%
76%	76%
75%	75%
74%	74%
73%	73%
72%	72%
71%	71%
70%	70%
69%	69%
68%	68%
67%	67%
66%	66%
65%	65%
64%	64%
63%	63%
62%	62%
61%	61%
60%	60%
59%	59%
58%	58%
57%	57%
56%	56%
55%	55%
54%	54%
53%	53%
52%	52%
51%	51%
50%	50%
49%	49%
48%	48%
47%	47%
46%	46%
45%	45%
44%	44%
43%	43%
42%	42%
41%	41%
40%	40%
39%	39%
38%	38%
37%	37%
36%	36%
35%	35%
34%	34%
33%	33%
32%	32%
31%	31%
30%	30%
29%	29%
28%	28%
27%	27%
26%	26%
25%	25%
24%	24%
23%	23%
22%	22%
21%	21%
20%	20%
19%	19%
18%	18%
17%	17%
16%	16%
15%	15%
14%	14%
13%	13%
12%	12%
11%	11%
10%	10%
9%	9%
8%	8%
7%	7%
6%	6%
5%	5%
4%	4%
3%	3%
2%	2%
1%	1%
0%	0%

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives and goals of the project. This helps to clarify what needs to be achieved and provides a clear direction for the team.

3. The third step is to develop a plan or strategy to address the problem. This involves breaking down the problem into smaller, manageable tasks and determining the resources needed to complete each task.

4. The fourth step is to implement the plan. This involves putting the strategy into action and monitoring progress regularly to ensure that the project is on track.

5. The final step is to evaluate the results of the project. This involves comparing the actual outcomes against the objectives and goals to determine the effectiveness of the project.

09157

Respectfully submitted,
GENENTECH, INC.

-6-